REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot99010.21518/1561-5936-2020-9-39-42Научная статьяA breakthrough in the treatment of chronic lymphocytic leukemiaProzherinaYuliyanoemail@neicon.ruShirokovaIrinanoemail@neicon.ruRM Analytics LLCRemedium091220209394218032022Copyright © 2020,2020Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Its prevalence is expected to increase alongside rising overall survival rates in patients with CLL achieved due to advances in therapy [1]. B-cell receptor signalling through Bruton’s tyrosine kinase (BTK) is one of the main pathways for the development of CLL. Acalabrutinib, the second-generation VTK inhibitor, has been made available recently to Russian patients, which presence in the market can improve the prognosis for such patients.chronic lymphocytic leukemiamantle cell lymphomaBruton’s tyrosine kinase inhibitorsacalabrutinibхронический лимфоцитарный лейкозмантийноклеточная лимфомаингибиторы тирозинкиназыБрутонаакалабрутиниб[American Cancer Society. Key Statistics for Chronic Lymphocytic Leukemia. Accessed February, 2020. Available at: https://www. cancer.org/cancer/chronic-lymphocytic-leukemia/about/key- statistics.html.][Бялик Т.Е., Зарицкий А.Ю., Исебер Лоик Капланов К.Д. Лопаткина Т.Н., Луговская С.А. и др. Хронический лимфоцитарный лейкоз/лимфома из малых лимфоцитов: клинические рекомендации. М.; 2020. 65 с. Режим доступа: https://rusoncohem.ru/wp-content/uploads/2019/11/ Hronicheskii%CC%86_limfoczitarnyi%CC%86_lei%CC%86koz_.pdf.][Пресс-релиз компании AstraZeneca. Клиническая онкогематология. 2020;(2):231-234. Режим доступа: http:// bloodjournal.ru/wp-content/uploads/2020/03/12.pdf.][Isaac K., Mato A.R. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data. Cancer Manag Res. 2020;12:2079-2085. doi: 10.2147/CMAR.S219570.][Doti C. Acalabrutinib in Chronic Lymphocytic Leukaemia. Published Online: August 27th 2020. Available at: https:// touchoncology.com/insight/acalabrutinib-in-chronic- lymphocytic-leukaemia-an-expert-interview-with-carlos-doti/.][Исследование препарата акалабрутиниб. Пресс-релиз компании «АстраЗенека» 30.12.2019. Режим доступа: https:// rusoncohem.ru/issledovanie-preparata-akalabrutinib/#.][Leick E. Brown Highlights the Future of Acalabrutinib in CLL Treatment. In: Conference International Conference on Malignant Lymphoma. June 20, 2019. Available at: https://www.onclive. com/view/brown-highlights-the-future-of-acalabrutinib-in-cll- treatment.][Поддубная И.В., Аль-Ради Л.С., Бялик Т.Е., Капланов К.Д., Молоствова В.З., Никитин Е.А. и др. Исследование ELEVATE- TN. Новые данные по акалабрутинибу в 1-й линии терапии хронического лимфоцитарного лейкоза. Резолюция. Современная онкология. 2020;22(1):31-33. doi: 10.26442/18151434. 2020.1.200090.][AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19. Available at: https://www.astrazeneca.com/content/ astraz/media-centre/press-releases/2020/astrazeneca-initiates- calavi-clinical-trial-with-calquence-against-covid-19.html.]